CBU
AGIO icon

CIBC Bancorp USA’s Agios Pharmaceuticals AGIO Stock Holding History

CIBC Bancorp USA’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$242K Buy
+6,021
New +$226K ﹤0.01% 1184

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CIBC Bancorp USA's AGIO Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in Agios Pharmaceuticals (AGIO) in Q3 2025: 6,021 shares worth $242K. The stake represents ﹤0.01% of the portfolio and ranks #1184 among its holdings.

220 funds tracked by Wall St. Rank hold AGIO as of Q3 2025.

  • CIBC Bancorp USA held 6,021 shares of Agios Pharmaceuticals worth $242K as of Q3 2025.
  • Agios Pharmaceuticals was a new CIBC Bancorp USA position in Q3 2025.
  • Agios Pharmaceuticals made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #1184 holding.
  • 220 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.